It has been reported that the prognosis of endometrial cancer was significantly worse for long-term tamoxifen users than for non-users, which seems to be due to higher stage and less-favorable histology, such as MMMTs or sarcomas, p53-positive tumors, and ER-negative tumors (Bergman et al. 2000). This evidence concerns the gene TP53 and endometrial cancer.